Dutch biotech company Micreos has appointed Dr Johan Frieling as its new chief scientific officer.
In his new role Dr Frieling will be responsible for overseeing Micreos’ antibiotic alternative, Staphefekt, as it begins clinical trials.
Mark Offerhaus, founder and chief executive officer of Micreos, said: “Johan has successfully developed a number of biopharmaceutical products up to FDA and EMA approval.
“For us he is the ideal person to lead Staphefekt to market in the new indications.”
Dr Frieling has over 20 years of clinical development experience and has previously held senior positions at Bayer, Genzyme and Pharmasquire Consultancy.
He joins Micreos from LFB Biotechnologies where he served most recently as director of global clinical research, with responsibility for all development products at the company.
Dr Freiling said: “It’s a great time to be joining Micreos … I look forward to sharing my knowledge and leading the clinical development of Staphefekt, ultimately helping a large cohort of patients across the globe.”